Previous 10 | Next 10 |
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical tri...
2023-12-20 12:00:32 ET Summary Liquidia Corporation is worth at least $15 in a win. Roivant Sciences is worth at least $12 per share. Burford Capital Limited is worth at least $20 per share. Value & Event Driven Investing I recently spoke for a half an hour a...
2023-12-20 08:36:29 ET Losers: Bluebird bio BLUE -52% on pricing of $125 million stock offering . Jin Medical International Ltd ( ZJYL ) -14% . Argen X SE ( ARGX ) -25% reports topline results from address study of Efgartigimod SC in Pemphigus . ...
BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upfront payment of approximately $7.1 billion. Telavant holds the r...
2023-12-12 20:24:54 ET Summary Ole Andreas Halvorsen's 13F stock portfolio value increased slightly to $24.64B, with 80 holdings. The largest positions in the portfolio are Visa, Workday, Amazon.com, United Parcel Service, and Danaher Corp. New stakes include Block Inc., Freep...
2023-12-04 21:29:35 ET Summary Baker Brothers' 13F portfolio value increased marginally from $17.28B to $17.35B. The largest five stakes in the portfolio are Seagen, BeiGene, Incyte, ACADIA Pharma, and BioMarin Pharma, making up approximately 86% of the portfolio. Stake increa...
2023-11-28 15:30:17 ET More on Immunovant Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrad...
Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402 IMVT-1402 was observed to deliver dose dependent and deep IgG reductions similar to batoclimab in its Phase 1 study IMVT-1402 600 mg was observed to deliver ...
2023-11-27 11:19:40 ET More on Roivant Sciences Roivant Sciences Ltd. (ROIV) Q2 2023 Earnings Call Transcript Roivant Sciences Ltd. 2023 Q2 - Results - Earnings Call Presentation Roivant Sciences: Risk-Transforming Deal Met With Crickets Biggest stock movers ...
2023-11-27 08:12:58 ET More on pre-market losers stock. Financial information for Anghami Financial information for Safe and Green Development Corporation For further details see: ANGH and SGD among pre-market losers
News, Short Squeeze, Breakout and More Instantly...
Roivant Sciences Ltd. Company Name:
ROIV Stock Symbol:
NASDAQ Market:
Roivant Sciences Ltd. Website:
2024-06-02 17:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update. Once-daily brepocitinib produced the best Treatment Failure...
BASEL, Switzerland and LONDON and NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 30, 2024, to report its financial results for the fourth quarter and fiscal year ended March 31...